Literature DB >> 26960712

Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.

Lisa Vetter1, Monika Keller2, Thomas Bruckner3, Michael Golatta1, Sabine Eismann1, Christina Evers4, Nicola Dikow4, Christof Sohn1, Jörg Heil1, Sarah Schott5,6.   

Abstract

Breast cancer (BC) is the leading cancer among women worldwide and in 5-10 % of cases is of hereditary origin, mainly due to BRCA1/2 mutations. Therefore, the German Consortium for Familial Breast and Ovarian Cancer (HBOC) with its 15 specialized academic centers offers families at high risk for familial/hereditary cancer a multimodal breast cancer surveillance program (MBCS) with regular breast MRI, mammography, ultrasound, and palpation. So far, we know a lot about the psychological effects of genetic testing, but we know little about risk-correlated adherence to MBCS or prophylactic surgery over time. The aim of this study was to investigate counselees' adherence to recommendations for MBCS in order to adjust the care supply and define predictors for incompliance. All counselees, who attended HBOC consultation at the University Hospital Heidelberg between July 01, 2009 and July 01, 2011 were eligible to participate. A tripartite questionnaire containing sociodemographic information, psychological parameters, behavioral questions, and medical data collection from the German consortium were used. A high participation rate was achieved among the study population, with 72 % returning the questionnaire. This study showed a rate of 59 % of full-adherers to the MBCS. Significant predictors for partial or full adherence were having children (p = 0.0221), younger daughters (p = 0.01795), a higher awareness of the topic HBOC (p = 0.01795, p < 0.0001), a higher perceived breast cancer risk (p < 0.0001), and worries (p = 0.0008)/impairment (p = 0.0257) by it. Although the current data suggest a good adherence of MBCS, prospective studies are needed to understand counselees' needs to further improve surveillance programs and adherence to them. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening-a monocenter study in Germany.

Entities:  

Keywords:  Adherence; BRCA mutation; Breast cancer; Cancer surveillance program; Compliance

Mesh:

Substances:

Year:  2016        PMID: 26960712     DOI: 10.1007/s10549-016-3748-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Authors:  Rodrigo Santa Cruz Guindalini; Yonglan Zheng; Hiroyuki Abe; Kristen Whitaker; Toshio F Yoshimatsu; Tom Walsh; David Schacht; Kirti Kulkarni; Deepa Sheth; Marion S Verp; Angela R Bradbury; Jane Churpek; Elias Obeid; Jeffrey Mueller; Galina Khramtsova; Fang Liu; Akila Raoul; Hongyuan Cao; Iris L Romero; Susan Hong; Robert Livingston; Nora Jaskowiak; Xiaoming Wang; Marcio Debiasi; Colin C Pritchard; Mary-Claire King; Gregory Karczmar; Gillian M Newstead; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Clin Cancer Res       Date:  2018-08-28       Impact factor: 12.531

2.  Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.

Authors:  Christina Evers; Christine Fischer; Nicola Dikow; Sarah Schott
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

3.  Is risk-stratified breast cancer screening economically efficient in Germany?

Authors:  Matthias Arnold; Katharina Pfeifer; Anne S Quante
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

4.  Relationship of attitudes toward uncertainty and preventive health behaviors with breast cancer screening participation.

Authors:  Miho Satoh; Naoko Sato
Journal:  BMC Womens Health       Date:  2021-04-21       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.